A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis

BACKGROUND: Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Dermatol
Main Authors: Lee, Joo-Heung, Youn, Jai-Il, Kim, Tae-Yoon, Choi, Jee-Ho, Park, Chul-Jong, Choe, Yong-Beom, Song, Hae-Jun, Kim, Nack-In, Kim, Kwang-Joong, Lee, Jeung-Hoon, Yoo, Hyun-Jeong
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4960797/
https://ncbi.nlm.nih.gov/pubmed/27455955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12895-016-0048-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados